GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
GO:000699713 | Esophagus | ESCC | nucleus organization | 96/8552 | 133/18723 | 4.66e-10 | 1.21e-08 | 96 |
GO:00987812 | Esophagus | ESCC | ncRNA transcription | 45/8552 | 56/18723 | 1.05e-07 | 1.72e-06 | 45 |
GO:007064612 | Esophagus | ESCC | protein modification by small protein removal | 95/8552 | 157/18723 | 1.25e-04 | 8.56e-04 | 95 |
GO:00093011 | Esophagus | ESCC | snRNA transcription | 16/8552 | 19/18723 | 6.45e-04 | 3.43e-03 | 16 |
GO:00182056 | Oral cavity | OSCC | peptidyl-lysine modification | 216/7305 | 376/18723 | 2.32e-13 | 1.16e-11 | 216 |
GO:00069974 | Oral cavity | OSCC | nucleus organization | 85/7305 | 133/18723 | 5.12e-09 | 1.12e-07 | 85 |
GO:00987811 | Oral cavity | OSCC | ncRNA transcription | 38/7305 | 56/18723 | 1.15e-05 | 1.18e-04 | 38 |
GO:00706462 | Oral cavity | OSCC | protein modification by small protein removal | 77/7305 | 157/18723 | 6.55e-03 | 2.43e-02 | 77 |
GO:0009301 | Oral cavity | OSCC | snRNA transcription | 13/7305 | 19/18723 | 9.07e-03 | 3.26e-02 | 13 |
GO:001820521 | Oral cavity | EOLP | peptidyl-lysine modification | 72/2218 | 376/18723 | 2.38e-05 | 3.56e-04 | 72 |
GO:007064611 | Oral cavity | EOLP | protein modification by small protein removal | 33/2218 | 157/18723 | 7.04e-04 | 5.78e-03 | 33 |
GO:000699721 | Oral cavity | EOLP | nucleus organization | 29/2218 | 133/18723 | 7.82e-04 | 6.24e-03 | 29 |
GO:0030575 | Oral cavity | EOLP | nuclear body organization | 6/2218 | 16/18723 | 7.66e-03 | 3.66e-02 | 6 |
GO:001820531 | Oral cavity | NEOLP | peptidyl-lysine modification | 64/2005 | 376/18723 | 1.21e-04 | 1.43e-03 | 64 |
GO:00069973 | Oral cavity | NEOLP | nucleus organization | 27/2005 | 133/18723 | 7.89e-04 | 6.27e-03 | 27 |
GO:00305751 | Oral cavity | NEOLP | nuclear body organization | 6/2005 | 16/18723 | 4.64e-03 | 2.56e-02 | 6 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
USPL1 | SNV | Missense_Mutation | | c.2994N>T | p.Met998Ile | p.M998I | Q5W0Q7 | protein_coding | deleterious(0.01) | benign(0.328) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
USPL1 | SNV | Missense_Mutation | | c.671N>A | p.Ala224Asp | p.A224D | Q5W0Q7 | protein_coding | tolerated(0.21) | benign(0.001) | TCGA-A7-A13D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
USPL1 | SNV | Missense_Mutation | | c.272N>A | p.Ser91Tyr | p.S91Y | Q5W0Q7 | protein_coding | deleterious(0) | probably_damaging(0.939) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
USPL1 | SNV | Missense_Mutation | rs756082560 | c.1183N>T | p.Gly395Cys | p.G395C | Q5W0Q7 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AN-A04D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
USPL1 | SNV | Missense_Mutation | | c.2851N>A | p.Glu951Lys | p.E951K | Q5W0Q7 | protein_coding | tolerated(1) | benign(0) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
USPL1 | SNV | Missense_Mutation | | c.484N>A | p.Pro162Thr | p.P162T | Q5W0Q7 | protein_coding | tolerated(0.1) | possibly_damaging(0.755) | TCGA-BH-A18R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
USPL1 | SNV | Missense_Mutation | | c.1954N>G | p.Ile652Val | p.I652V | Q5W0Q7 | protein_coding | tolerated(0.55) | benign(0.001) | TCGA-E2-A15S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
USPL1 | SNV | Missense_Mutation | novel | c.2621C>T | p.Ser874Leu | p.S874L | Q5W0Q7 | protein_coding | tolerated(0.09) | benign(0.118) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
USPL1 | SNV | Missense_Mutation | novel | c.3122C>G | p.Ser1041Cys | p.S1041C | Q5W0Q7 | protein_coding | deleterious(0.01) | probably_damaging(0.912) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
USPL1 | insertion | Nonsense_Mutation | novel | c.3181_3182insACTGATTTACAACCTTCAGTTAAAGGGGTAAATAATTTTGGTGGC | p.Ile1061delinsAsnTerPheThrThrPheSerTerArgGlyLysTerPheTrpTrpLeu | p.I1061delinsN*FTTFS*RGK*FWWL | Q5W0Q7 | protein_coding | | | TCGA-A8-A07P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |